Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. - Wikidata - wikimedia - TriplyDB

Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy.

Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy.

http://www.wikidata.org/entity/Q42169441

about

The role of urotensin II in cardiovascular and renal physiology and diseases Association analysis of urotensin II gene (UTS2) and flanking regions with biochemical parameters related to insulin resistance Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol Human cardiomyopathy mutations induce myocyte hyperplasia and activate hypertrophic pathways during cardiogenesis in zebrafish The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.Urotensin II inhibited the proliferation of cardiac side population cells in mice during pressure overload by JNK-LRP6 signalling GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems Potential Clinical Implications of the Urotensin II Receptor Antagonists.The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy Urotensin-II and the cardiovascular system--the importance of developing modulators.Urotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S Pathway An investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat hearts Urotensin-II induces ear flushing in rats A closer look at the role of urotensin II in the metabolic syndrome.Urotensin-II Immunoreactivity in Normolipidemic and Hyperlipidemic New Zealand White Rabbits Following Balloon Angioplasty and Stenting.Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?Urotensin II in cardiovascular regulation.Effect of KIOM-79 on Diabetes-Induced Myocardial Fibrosis in Zucker Diabetic Fatty Rats.Direct inotropic effects of exogenous and endogenous urotensin-II: divergent actions in failing and nonfailing human myocardium.PPAR-gamma expression in animals subjected to volume overload and chronic Urotensin II administration.Plasma urotensin II and neurokinin B levels in acute myocardial infarction and stable coronary artery disease.Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes.Role of urotensin II in health and disease.Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests.Immunopathogenesis of Myocarditis: The Interplay Between Cardiac Fibroblast Cells, Dendritic Cells, Macrophages and CD4+ T Cells.A novel role of G protein-coupled receptor kinase 5 in urotensin II-stimulated cellular hypertrophy in H9c2UT cells.The role of neuropeptides in adverse myocardial remodeling and heart failure.Urotensin II induces transactivation of the epidermal growth factor receptor via transient oxidation of SHP-2 in the rat renal tubular cell line NRK-52E.Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction.Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease.Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension.Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.Kidney is in trouble with mediators.The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans.

P2860

Q24675590-437EDF05-EBC9-473B-9C0A-F4403D7F215E Q28478002-99674E67-7507-4DA8-B9BE-C498A953E978 Q28572971-FE0970D7-412A-4232-B242-554B56E83901 Q28573864-AE6E796D-C5FA-4D27-BA4B-5B86C459CB0F Q30500300-1229DBE6-FF22-44AB-9E0F-0495B4A5995B Q33599835-75DA40C0-F592-46FF-AE67-5DADEC63EA59 Q33991646-127F6247-3B25-47E9-B68F-AFFFE0AA98CC Q34233981-FC6E080B-8B96-40BE-BFAA-94741399E93E Q34248766-0040F566-3AA8-4B0F-B9AE-70B8F82A59C6 Q35047377-7E2CA507-9AFB-46CE-9B8C-FA33676DE369 Q35048941-E054BF58-913C-4469-9352-92D15E4F377C Q35100902-09E1F92A-9AC7-4EFB-B538-EF83656D7CF6 Q35128456-AD20BE0D-49D4-490A-9D73-FCBE95E14DA7 Q35538538-37B4C1A1-1F5B-4166-8C9C-4E3EB1B5A3F6 Q35779239-43F09715-B868-49E8-BF76-F1F599286DE7 Q35813861-B91E2A7F-95F8-493E-BEE5-0D6DD3089D20 Q36224889-5C930F27-D558-484B-B09E-122E4CDAE140 Q36357772-A66E818D-B2EA-416B-97D8-04F004478EDF Q36492706-C7A41E92-5C62-472D-B9B5-6C713BE6664D Q36735227-2651B507-648E-4563-9798-F62F073F52E6 Q37015817-C4BE65AD-CB4D-493E-BF2D-5B6572591331 Q37082781-393BC2B8-3CAA-4602-BE2F-048D0FA8AB73 Q37344439-CFFE5BB2-E75C-466A-9E0C-4EE4BA60CFFB Q37353581-AFA5E25C-F346-4C63-A2BC-C50B908683BF Q37394539-99B8CC49-7F6E-4553-9D7F-48573EC600B4 Q37422701-7677F749-4DDF-4C77-A1A3-4D53B50E796D Q37680436-3B2E11A1-F9CC-4E2C-B521-C9C695AEF37C Q37728377-5DC83078-B16C-49DA-A225-964F2626195D Q37737495-9B0EDF04-35A5-4838-84C1-4564D481F702 Q37970489-176D85E2-5E3E-4CD2-A3F2-0B1CD881CFC2 Q38407555-4B82CCEC-B076-4D0E-BB5F-19E1E143200C Q38747134-C2B4AC34-3335-4188-8EC3-1E3FB565B1B1 Q39093111-0A48DB32-8CCD-4D6C-B32D-7E8CE21F75FE Q39867550-A847183F-0BB1-4C60-AED5-94C22AA39680 Q39939179-703A461C-6361-4202-B3BA-FFD6A709844C Q40122555-BCFC3AA4-BA1B-4945-BA18-09D6A4D0FBB1 Q40166897-2E8A07AB-71FE-4784-B368-2E2FEFD3E379 Q40430686-B5AE0DA3-1742-47FF-BB26-ADED09B77C1A Q42280581-DFAEBA58-7F3A-44C4-9BF9-2C9C21E0B19F Q42283626-D6D1D1BA-2BB5-4859-8CF6-192592E7AE8F

P2860

Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy.

http://www.wikidata.org/entity/Q42169441

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Direct actions of urotensin II ...... diac fibrosis and hypertrophy.

@en

Direct actions of urotensin II ...... diac fibrosis and hypertrophy.

@nl

type

label

Direct actions of urotensin II ...... diac fibrosis and hypertrophy.

@en

Direct actions of urotensin II ...... diac fibrosis and hypertrophy.

@nl

prefLabel

Direct actions of urotensin II ...... diac fibrosis and hypertrophy.

@en

Direct actions of urotensin II ...... diac fibrosis and hypertrophy.

@nl

P1433

Q42169441-7322F0E2-0E86-427D-BE93-B0CE3B9460A9

P1476

Q42169441-C942278F-0387-4AA0-90C1-419EFEA792E0

P2093

Q42169441-29C4E273-221D-4116-B633-2CEE1235AFA5

Q42169441-3242D12F-5E1A-421F-8FE4-997DAC7BB179

Q42169441-98D87BC9-9EB0-4EAB-B148-A1EE28B07FEA

Q42169441-9D4B824E-FD87-4896-9231-1D2C6AF7ED7C

Q42169441-A1059655-B6EA-4803-A351-06E95322D825

Q42169441-CBAA0107-1171-4ADE-9BE2-9465E6385431

Q42169441-DABD4AE1-2818-4ED8-96EB-B5E226FFB086

Q42169441-FBA6D93B-F4F8-46E1-B971-87EB374F16D3

P304

Q42169441-E790F43A-932B-428D-89CC-F27E91DA8BEB

P31

Q42169441-DE423C6C-C719-4933-88F9-3D2BC16DA07D

P356

Q42169441-49AD261E-6E9E-461C-B842-204F5F9EDC6F

P433

Q42169441-64E9A751-734B-4F54-8A1F-E3556B83DDD1

P478

Q42169441-8870D588-6C26-4D9F-9A20-F100AD80BB75

P50

Q42169441-AF9276E5-C934-4AA9-802C-9282C14DE2ED

P577

Q42169441-507F62C6-B6AB-4504-93AC-AB3B556FCF15

P5875

Q42169441-836AB766-9C9B-4CBD-8D0A-207D43174E9E

P698

Q42169441-5711E5D8-8EB2-414A-9176-FD89AB324011

P356

01.RES.0000084382.64418.BC

P1433

Circulation Research

P1476

Direct actions of urotensin II ...... diac fibrosis and hypertrophy.

@en

P2093

Alex Tzanidis

http://www.w3.org/2001/XMLSchema#string

Darren J Kelly

http://www.w3.org/2001/XMLSchema#string

Dominic J Autelitano

http://www.w3.org/2001/XMLSchema#string

Döne Onan

http://www.w3.org/2001/XMLSchema#string

Fiona See

http://www.w3.org/2001/XMLSchema#string

Richard E Gilbert

http://www.w3.org/2001/XMLSchema#string

Ross D Hannan

http://www.w3.org/2001/XMLSchema#string

Walter G Thomas

http://www.w3.org/2001/XMLSchema#string

P304

246-253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.RES.0000084382.64418.BC

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10676652

http://www.w3.org/2001/XMLSchema#string

P698

12842917

http://www.w3.org/2001/XMLSchema#string